



March 6, 2026

For Immediate Release

Company Name:	Sumitomo Chemical Co., Ltd.
Representative:	Nobuaki Mito President and Representative Director
Securities Code:	4005
Stock Exchange Listings:	Prime Section of the Tokyo Stock Exchange
Inquiries:	Shunji Kobayashi General Manager Corporate Communications Dept. (Tel: +81-3-5201-0200)

### **Notice Regarding a Subsidiary Obtaining Manufacturing and Marketing Authorization for iPS Cell-Derived Product “AMCHEPRY®” for the Treatment of Parkinson's Disease**

Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma,” a subsidiary in which Sumitomo Chemical holds a 51.76% ownership stake), and RACTHERA Co., Ltd. (“RACTHERA,” a joint venture in which Sumitomo Chemical holds a 66.6% ownership stake and Sumitomo Pharma holds a 33.4% ownership stake) have announced that Sumitomo Pharma has obtained, as of March 6, 2026, manufacturing and marketing authorization (conditional and time-limited approval) for its allogeneic iPS cell-derived dopaminergic neural progenitor cell product AMCHEPRY® (“the Product”) in Japan. This marks the world’s first-ever approval of a regenerative medicine and cell therapy product derived from iPS cells. For more information, please see the attached document.

Sumitomo Chemical is working to solve four key issues related to the creation of societal value. Of these key issues, in the area of healthcare, the Company has positioned its regenerative medicine and cell therapy business as a core part of its new medium- to long-term growth areas. Sumitomo Chemical has made sustained efforts across the entire Group in stem cell research and toward the practical implementation of regenerative and cellular therapies, and views this approval as a significant milestone in these longstanding initiatives.

The Product is expected to become a blockbuster product that will generate over 100 billion yen in sales in the 2030s. In addition, the Product’s manufacturing will be handled by S-RACMO Co., Ltd. (“S-RACMO,” a joint venture in which Sumitomo Chemical holds a 66.6% ownership stake and Sumitomo Pharma holds a 33.4% ownership stake), a contract development and manufacturing organization with experience in the commercial production of regenerative and cellular therapies, which already plays a pioneering role in the manufacturing of a wide variety of regenerative and cellular therapies.

Sumitomo Chemical, Sumitomo Pharma, RACTHERA, and S-RACMO will continue to work together to expand the regenerative and cellular therapy business, delivering new innovative treatments to patients as solutions in the healthcare field, including advanced medical care, and thereby contribute to solving societal issues.

March 6, 2026

Sumitomo Pharma Co., Ltd.  
RACTHERA Co., Ltd.

**Announcement on the Approval for Manufacturing and Marketing  
Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural  
Progenitor Cell Product “AMCHEPRY®” in Japan**

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Toru Kimura; “Sumitomo Pharma”) and RACTHERA Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan; President and CEO: Atsushi Ikeda; “RACTHERA”) announce that Sumitomo Pharma has obtained, as of March 6, 2026, conditional and time-limited approval in Japan for the manufacturing and marketing authorization of the allogeneic iPS cell-derived dopaminergic neural progenitor cell product AMCHEPRY® (INN: raguneprocel; the “Product”) for the indication of the improvement of motor symptoms in patients with Parkinson’s disease who have an inadequate response to existing pharmacological therapies, including levodopa-containing products.

The Product is the world’s first iPS cell-derived regenerative medicine. Based on the data from an investigator-initiated clinical study\*<sup>1</sup> conducted by Kyoto University Hospital, Sumitomo Pharma submitted its an application for manufacturing and marketing authorization on August 5, 2025, and has now obtained the conditional and time-limited approval.

Following the National Health Insurance price listing, Sumitomo Pharma will be responsible for marketing of the Product, and S-RACMO Co., Ltd. (Head Office: Suita, Osaka, Japan; President and CEO: Atsushi Tsuchida) will be responsible for manufacturing.

Sumitomo Pharma will conduct a post-marketing clinical study and a post-marketing surveillance to obtain full approval within the designated period.

Sumitomo Pharma and RACTHERA aim to provide patients with Parkinson’s disease with a new treatment option that differs from conventional pharmacotherapies and to further contribute to advances in the treatment of Parkinson’s disease.

\*<sup>1</sup> The results of the clinical study were published in *Nature* in April 2025

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease | *Nature* 641, 971–977 (2025)

<https://doi.org/10.1038/s41586-025-08700-0>

\* The Product has been receiving ongoing research support from the Japanese government through programs funded by the Japan Agency for Medical Research and Development (AMED), including the Research Center Network for Realization of Regenerative Medicine, the Research Project for Practical Applications of Regenerative Medicine, and the Project Focused on Developing Key Evaluation Technology, among others.

(Reference)

About AMCHEPRY®(INN: raguneprocel)

The Product contains non-frozen dopaminergic neural progenitor cells manufactured through differentiation of allogeneic iPS cells. Dopamine is a neurotransmitter, which is produced in dopaminergic neurons. Dopaminergic neural progenitor cells are cells that have not yet differentiated into dopaminergic neurons. The Product received the SAKIGAKE Designation for regenerative medical products in February 2017 and was designated as an orphan regenerative medical product in December 2025 from the Ministry of Health, Labour and Welfare.

#### RACTHERA

RACTHERA is a joint venture between Sumitomo Chemical Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan; “Sumitomo Chemical”) and Sumitomo Pharma. The company began operations on February 1, 2025, after inheriting intellectual property and other assets related to the regenerative and cellular medicine business from Sumitomo Pharma. RACTHERA serves as the core organization for research and development in the Sumitomo Chemical Group’s regenerative and cellular medicine business and is engaged in the development of innovative therapies utilizing iPS cells and other modalities.

#### S-RACMO

S-RACMO is a joint venture between Sumitomo Chemical and Sumitomo Pharma and operates as a Contract Development and Manufacturing Organization (CDMO) that undertakes process development and manufacturing of regenerative and cellular medicine products. The Product will be manufactured at “SMaRT” (Suita, Osaka), the world’s first commercial-scale manufacturing facility dedicated to regenerative and cellular medicine products derived from allogeneic iPS cells.

#### The technology for manufacturing iPS cell-derived dopaminergic neural progenitor cells:

The Product contains the dopaminergic neural progenitor cells differentiated from iPS cells stock provided by CiRA Foundation based on differentiation and manufacturing technology owned by Kyoto University and other parties. In addition, the Product, in one of its production steps for dopaminergic neural progenitor cells, employs a proprietary cell purification technology discovered by KAN Research Institute, Inc. (currently Kobe Research Laboratories, Eisai Co., Ltd.) and owned by Eisai Co., Ltd.

#### Contact:

Corporate Communications, Corporate Governance Sumitomo Pharma Co., Ltd.

E-mail: [prir@sumitomo-pharma.co.jp](mailto:prir@sumitomo-pharma.co.jp)

Business Administration Department, RACTHERA Co., Ltd.

E-mail: [contact@racthera.co.jp](mailto:contact@racthera.co.jp)